BioMarin Q3 revenue up 24% YoY to $505M; VOXZOGO guidance raised to $140-170M

BIOMARIN PHARMACEUTICAL INC

2022-Q3 EPS reported $0.75 revenue$1,558,501,000

Total revenues $505.3M (+24% YoY); GAAP net loss narrowed to $6.7M from $36.5M; Non-GAAP income $82.7M.
VOXZOGO net product revenue $48.3M, with 713 children treated; full-year guidance raised to $140-170M.
ROCTAVIAN BLA accepted by FDA, PDUFA March 31, 2023; EU commercial launch underway after August 2022 approval.
KUVAN revenue fell 16% QoQ and 20% YTD due to U.S. generic competition, as expected.
Full-year total revenue guidance reaffirmed at $2.06-2.16B; R&D and SG&A guidance ranges revised modestly.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.